Peter S. Nelson

TL;DR: A non‐methyltransferase function of EZH2 that controls protein translation of p53 GOF mutants, inhibition of which causes synthetic lethality in cancer cells expressing p53 GoF mutants is revealed.

TL;DR: In vitro and in vivo growth responses of Abi-/Enza-resistant LNCaP-95 cells in which CRISPR-Cas9 was used to knockout AR-FL or AR-V7 alone or in combination were evaluated, and RNAseq analysis demonstrates that both AR- FL- and AR- V7-dependent transcriptional complementation are needed for Abi/ Enza resistance.

TL;DR: In vitro high-throughput RNA interference screen identifies pathways in androgen-dependent prostate cancer cell lines whose loss-of-function promotes androgen ligand-independent growth and shows that loss of PPP2R2C promotes androgens ligand depletion-resistant prostate cancer growth without altering AR expression or canonical AR-regulated gene expression.

TL;DR: The TMPRSS2‐ERG gene fusion is detected in approximately half of primary prostate cancers (PCa) yet the prognostic significance remains unclear, and it is hypothesized that ERG promotes the expression of common genes in primary PCa and metastatic castration‐resistant PCa.

TL;DR: 17β-estradiol significantly suppressed tumor T and DHT and inhibits growth of CRPC in an estrogen receptor independent manner and the ability to manipulate tumoral androgens will be critical in the development and testing of agents targeting CRPC through tissue steroidogenesis.